Castration-sensitive Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-sensitive Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial [Phase 2]
DIVINE is a Phase 2 trial evaluating stereotactic body radiation therapy with either immediate or delayed androgen receptor pathway inhibito…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response [Phase 3]
Phase 3 clinical trial exploring switching from docetaxel to androgen receptor pathway inhibitors in metastatic castration-sensitive prostat…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer [Phase 1, Phase 2]
This clinical trial evaluates PDS01ADC in combination with docetaxel and abiraterone for metastatic castration-sensitive and metastatic cast…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents [Phase 3]
Phase 3 trial evaluating Saruparib (AZD5305) versus placebo in men with metastatic castration-sensitive prostate cancer receiving physician'…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. [Phase 3]
Phase 3 trial update evaluating whether combining mevrometostat with enzalutamide improves outcomes versus enzalutamide alone in ARPI-naïve …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial [Phase 2]
Phase 2 PRTY Trial evaluating FDG-PET-guided metastasis-directed radiation therapy for metastatic hormone-sensitive prostate cancer; current…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial [Phase 2]
A Phase 2 clinical trial (EQUIP) is evaluating estrogen therapy to improve quality of life for men with newly diagnosed or recurrent metasta…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) [Phase 2]
An ongoing Phase 2 clinical trial (A-DREAM) is evaluating whether interrupting hormonal therapy in exceptional responders with metastatic pr…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer [Phase 2]
Phase 2 clinical trial update of First Strike and Second Strike therapies for high-risk metastatic castration-sensitive prostate cancer, spo…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy [Phase 2]
Phase 2 clinical trial evaluating the combination of ipilimumab, degarelix, and radical prostatectomy in men with newly diagnosed metastatic…
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
This clinical trial investigates whether PSA biochemical response can serve as a prognostic factor in metastatic castration-sensitive prosta…
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: Remotely Monitored Exercise Interventions in Patients with MCSPC Undergoing ADT (Prostate 006) [NA]
A clinical trial update describes a remotely monitored exercise intervention for men with castration-sensitive or metastatic prostate cancer…